Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Induction of Tolerogenic Dendritic Cells by a PEGylated TLR7 Ligand for Treatment of Type 1 Diabetes.

PloS one - 1 Jan 2015

Hayashi Tomoko, Yao Shiyin, Crain Brian, Promessi Victor J, Shyu Luke, Sheng Caroline, Kang McNancy, Cottam Howard B, Carson Dennis A, Corr Maripat

Abstract excerpt

Autoimmune diabetes mellitus (DM) results from the destruction of pancreatic islet cells by activated T lymphocytes, which have been primed by activated dendritic cells (DC). Individualized therapy with ex vivo DC manipulation and reinfusion has been proposed as a treatment for DM, but this treatment is limited by cost, and requires specialized facilities. A means of in situ modulation of the DC phenotype in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adoptive Transfer
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Tolerance

Share to Immunomodulation

Share to Inflammation Mediators

Share to Mice, Inbred NOD

Share to T-Lymphocyte Subsets

Share to Toll-Like Receptor 7

Source

Open in PubMed Open full text

Identifiers

PMID: 26076454
DOI: 10.1371/journal.pone.0129867
PMCID: PMC4468074

Genes

TLR7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Induction of Tolerogenic Dendritic Cells by a PEGylated TLR7 Ligand for Treatment of Type 1 Diabetes.PMID 26076454Read ↗

Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype In Vitro and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses.Semantic proximity Read ↗

Type 1 regulatory T cells and regulatory B cells induced by tolerogenic dendritic cells.Semantic proximity Read ↗

Preproinsulin-specific regulatory T cell-derived exosomes loaded with immune checkpoint ligands can suppress autoimmune responses in type 1 diabetesSemantic proximity Read ↗

Activation of T cell checkpoint pathways during β-cell antigen presentation by engineered dendritic cells promotes protection of non-obese diabetic mice from type 1 diabetesSemantic proximity Read ↗

Immune intervention for type 1 diabetes mellitusSemantic proximity Read ↗

TLR7/9 versus TLR3/MDA5 signaling during virus infections and diabetesSemantic proximity Read ↗

Transcriptomic Analysis Identifies A Tolerogenic Dendritic Cell Signature.Semantic proximity Read ↗

CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences.Semantic proximity Read ↗

Toll-like receptor 7 deficiency suppresses type 1 diabetes development by modulating B-cell differentiation and functionSemantic proximity Read ↗

Hepatic Dendritic Cells, the Tolerogenic Liver Environment, and Liver Disease.Semantic proximity Read ↗

Hiltonol and Protamine-RNA stimulation induce an immune-activating transcriptome profile in cDC1sSemantic proximity Read ↗

Handbook of experimental pharmacology "dendritic cells": the use of dexamethasone in the induction of tolerogenic DCs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.